Latest Period
Q1 2026
Security Snapshot
Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION) Institutional Ownership
CUSIP: 829401108
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
118
Shares (Excl. Options)
45,355,548
Price
$40.09
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- SION on Nasdaq
- Shares outstanding
- 45,002,549
- Price per share
- $39.59
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 45,355,548
- Total reported value
- $1,813,291,553
- % of total 13F portfolios
- 0%
- Share change
- +1,305,444
- Value change
- +$51,501,235
- Number of holders
- 118
- Price from insider filings
- $39.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SION - Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 829401108.
- 118 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 101 to 118 between Q4 2025 and Q1 2026.
- Reported value moved from $1,808,143,956 to $1,813,291,553.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 118 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 829401108?
CUSIP 829401108 identifies SION - Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 829401108:
Significant Owners of Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23% | -4.6% | $296,218,114 | -$10,988,206 | 10,071,712 | -3.6% | RA Capital Management, L.P. | 05 Nov 2025 |
| TPG GP A, LLC | 15% | $80,486,942 | 6,684,962 | TPG GP A, LLC | 10 Feb 2025 | |||
| VIKING GLOBAL INVESTORS LP | 7.1% | +5.7% | $133,462,710 | +$10,126,176 | 3,195,181 | +8.2% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| ORBIMED ADVISORS LLC | 6.6% | -22% | $118,970,633 | -$29,554,504 | 2,967,722 | -20% | ORBIMED ADVISORS LLC | 15 Apr 2026 |
| Enavate Sciences GP, LLC | 5.6% | $29,835,481 | 2,478,030 | Enavate Sciences GP, LLC | 10 Feb 2025 | |||
| Atlas Venture Fund XI, L.P. | 5.4% | -16% | $74,744,824 | -$15,805,403 | 2,382,495 | -17% | Atlas Venture Fund XI, L.P. | 16 Oct 2025 |
| Qatar Investment Authority | 4.5% | -10% | $84,386,177 | -$7,916,125 | 2,020,258 | -8.6% | Qatar Investment Authority | 31 Mar 2026 |
| JPMORGAN CHASE & CO | 4.4% | -12% | $58,251,993 | -$7,075,145 | 1,980,626 | -11% | JPMORGAN CHASE & CO. | 30 Sep 2025 |
As of 31 Mar 2026, 118 institutional investors reported holding 45,355,548 shares of Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION). This represents 101% of the company’s total 45,002,549 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 22% | 9,905,045 | 0% | 4.2% | $397,093,254 |
| TPG GP A, LLC | 14% | 6,494,962 | -3.7% | 7.1% | $260,383,027 |
| ORBIMED ADVISORS LLC | 7.8% | 3,530,702 | -0.87% | 3.2% | $141,545,843 |
| VIKING GLOBAL INVESTORS LP | 7.1% | 3,195,181 | 0% | 0.36% | $128,094,806 |
| Atlas Venture Life Science Advisors, LLC | 6.7% | 2,995,602 | 0% | 15% | $120,093,684 |
| ENAVATE SCIENCES GP, LLC | 5.5% | 2,478,030 | 0% | 28% | $99,344,223 |
| JPMORGAN CHASE & CO | 3.3% | 1,465,014 | +19% | 0% | $53,707,413 |
| JENNISON ASSOCIATES LLC | 3.2% | 1,451,220 | +30% | 0.04% | $58,179,411 |
| BlackRock, Inc. | 2.9% | 1,295,867 | +0.33% | 0% | $51,951,309 |
| CITADEL ADVISORS LLC | 2.6% | 1,166,931 | +7.3% | 0.03% | $46,782,264 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 1,029,497 | 0% | 0% | $41,272,535 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.2% | 970,590 | 0% | 0.46% | $38,910,953 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.7% | 756,376 | -9% | 0% | $30,324,000 |
| STATE STREET CORP | 1.7% | 756,227 | +9.1% | 0% | $30,317,140 |
| PERCEPTIVE ADVISORS LLC | 1.5% | 658,439 | -44% | 0.52% | $26,396,820 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.4% | 645,530 | +1% | 0.43% | $25,875,888 |
| Aberdeen Group plc | 1.3% | 564,175 | -33% | 0.04% | $22,617,776 |
| BAKER BROS. ADVISORS LP | 0.89% | 400,000 | 0% | 0.09% | $16,036,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 389,872 | +2.6% | 0% | $15,633,527 |
| Siren, L.L.C. | 0.67% | 300,000 | 0% | 0.33% | $12,027,000 |
| Sio Capital Management, LLC | 0.65% | 294,340 | 1.7% | $11,800,091 | |
| Soleus Capital Management, L.P. | 0.65% | 293,500 | +9.3% | 0.48% | $11,766,415 |
| GOLDMAN SACHS GROUP INC | 0.58% | 263,174 | +626% | 0% | $10,550,646 |
| Ensign Peak Advisors, Inc | 0.57% | 255,636 | +220% | 0.02% | $10,248,447 |
| Candriam S.C.A. | 0.53% | 236,813 | 0.05% | $9,493,833 |
Institutional Holders of Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 45,355,548 | $1,813,291,553 | +$51,501,235 | $40.09 | 118 |
| 2025 Q4 | 43,950,880 | $1,808,143,956 | +$42,254,824 | $41.14 | 101 |
| 2025 Q3 | 42,840,564 | $1,259,943,482 | -$14,718,322 | $29.41 | 78 |
| 2025 Q2 | 43,448,393 | $753,831,077 | +$37,292,994 | $17.35 | 65 |
| 2025 Q1 | 41,491,947 | $434,056,422 | +$434,056,422 | $10.46 | 47 |